Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Lyell Immunopharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SOUTH SAN FRANCISCO, CALIF., JUNE 25, 2026 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED THAT MEMBERS OF ITS SENIOR MANAGEMENT TEAM WILL PARTICIPATE IN A FIRESIDE CHAT AT THE H.C.

LYELL IMMUNOPHARMA ANNOUNCES PARTICIPATION IN H.C. WAINWRIGHT 4TH ANNUAL CELL THERAPY VIRTUAL CONFERENCE

MORE THAN 100 PATIENTS TREATED WITH RONDE-CEL IN 2L AND 3L+ LBCL, WITH A MANUFACTURING SUCCESS RATE OF 97% NO GRADE  3 CRS AND LOW RATES OF GRADE  3 ICANS, SUPPORTING OUTPATIENT ADMINISTRATION TRANSLATIONAL DATASUPPORT BIOLOGICAL BASIS FOR DURABLE RESPONSES,INCLUDING ENHANCED MEMORY POTENTIAL OF CYTOTOXIC EFFECTOR CELLS FROM CD62L+ ENRICHMENT, AND CD19/CD20 DUAL-TARGETING TO OVERCOME LOW ANTIGEN EXPRESSION PINACLE PIVOTAL CLINICAL TRIAL IN 3L+ SETTING DATA UPDATE EXPECTED IN SECOND HALF OF 2026; PIVOTAL DATA READOUT EXPECTED IN MID-2027, WITH BLA SUBMISSION TO FOLLOW IN THE SECOND HALF OF 2027 SOUTH SAN FRANCISCO, CALIF., JUNE 12, 2026 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, IS ANNOUNCING TODAY NEW SAFETY DATA FROM THE ONGOING PHASE 1/2 CLINICAL TRIAL OF RONDECABTAGENE AUTOLEUCEL (RONDE-CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN THE SECOND-LINE (2L) AND THIRD- AND LATER-LINE (3L+) SETTINGS AND NEW TRANSLATIONAL DATA FOR RONDE-CEL.

LYELL IMMUNOPHARMA PRESENTS UPDATED SAFETY DATA AND TRANSLATIONAL INSIGHTS FOR RONDECABTAGENE AUTOLEUCEL (RONDE-CEL) IN PATIENTS WITH LARGE B-CELL LYMPHOMA AT EUROPEAN HEMATOLOGY ASSOCIATION 2026 CONGRESS

SOUTH SAN FRANCISCO, CALIF., JUNE 08, 2026 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY PROVIDED AN UPDATE ON THE SAFETY PROFILE OF LYL273 IN ITS ONGOING U.S. PHASE 1 CLINICAL TRIAL IN PATIENTS WITH RELAPSED OR REFRACTORY METASTATIC COLORECTAL CANCER (MCRC), AND ANNOUNCED THE PHASE 1 TRIAL HAS BEEN AMENDED TO ENABLE SEAMLESS EXPANSION INTO A POTENTIAL PIVOTAL SINGLE-ARM PHASE 2 TRIAL PENDING REGULATORY ALIGNMENT.

LYELL IMMUNOPHARMA PROVIDES UPDATE ON SAFETY PROFILE OF LYL273 IN RELAPSED OR REFRACTORY METASTATIC COLORECTAL CANCER AND AMENDS PHASE 1 TRIAL TO PHASE 1/2 EXPANSION

SOUTH SAN FRANCISCO, CALIF., JUNE 04, 2026 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED THAT THE COMPANY WILL PRESENT DATA FROM ITS ONGOING PHASE 1/2 CLINICAL TRIAL OF RONDECABTAGENE AUTOLEUCEL (RONDE-CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2026 CONGRESS, TAKING PLACE IN STOCKHOLM, SWEDEN, JUNE 1114, 2026. THE DATA WILL BE FEATURED IN TWO POSTER PRESENTATIONS COVERING AN UPDATED RONDE-CEL SAFETY ANALYSIS AND TRANSLATIONAL INSIGHTS.

LYELL IMMUNOPHARMA TO PRESENT PHASE 1/2 SAFETY AND TRANSLATIONAL DATA FOR RONDE-CEL IN LARGE B-CELL LYMPHOMA AT THE EUROPEAN HEMATOLOGY ASSOCIATION 2026 CONGRESS

SOUTH SAN FRANCISCO, CALIF., JUNE 01, 2026 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED THAT MEMBERS OF ITS SENIOR MANAGEMENT TEAM WILL PARTICIPATE IN THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE 2026 ON MONDAY, JUNE 8, 2026, IN MIAMI, FLORIDA, WITH A FIRESIDE CHAT SCHEDULED FOR 11:20 AM EASTERN TIME.

LYELL IMMUNOPHARMA ANNOUNCES PARTICIPATION IN GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE 2026

SOUTH SAN FRANCISCO, CALIF., MAY 12, 2026 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED THAT MEMBERS OF ITS SENIOR MANAGEMENT TEAM WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: H.C.

LYELL IMMUNOPHARMA ANNOUNCES PARTICIPATION IN MAY INVESTOR CONFERENCES

PINACLE PIVOTAL CLINICAL TRIAL EVALUATING RONDE-CEL IN PATIENTS WITH LBCL IN THIRD- OR LATER-LINE SETTING ON TRACK TO REPORT ADDITIONAL DATA IN SECOND HALF OF 2026, WITH PIVOTAL DATA EXPECTED MID-2027 AND BLA SUBMISSION EXPECTED TO FOLLOW IN 2027 PINACLE-H2H, A FIRST OF ITS KIND PHASE 3 CLINICAL TRIAL EVALUATING RONDE-CEL HEAD-TO-HEAD AGAINST STANDARD-OF-CARE CD19 CAR T-CELL THERAPIES IN THE LBCL SECOND-LINE SETTING, COMMENCED PATIENT DOSING PHASE 1 CLINICAL TRIAL OF LYL273 CONTINUES TO ENROLL PATIENTS WITH METASTATIC COLORECTAL CANCER, WITH COMMENCEMENT OF PATIENT DOSING AT DOSE LEVEL 3 CLOSED SECOND $50 MILLION TRANCHE OF $100 MILLION PRIVATE PLACEMENT AT $25.61 PER SHARE, WITH APPROXIMATELY $261 MILLION IN CASH AS OF MARCH31, 2026, EXPECTED TO PROVIDE RUNWAY INTO Q3 2027 SOUTH SAN FRANCISCO, CALIF., MAY 06, 2026 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY REPORTED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026.

LYELL IMMUNOPHARMA REPORTS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE FIRST QUARTER 2026

SOUTH SAN FRANCISCO, CALIF., APRIL 07, 2026 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED THAT MEMBERS OF ITS SENIOR MANAGEMENT TEAM WILL PRESENT AND PARTICIPATE IN THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE ON TUESDAY, APRIL 14, 2026, AT 11:00 AM EASTERN TIME.

LYELL IMMUNOPHARMA ANNOUNCES PARTICIPATION IN 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

SOUTH SAN FRANCISCO, CALIF., MARCH 12, 2026 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY REPORTED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2025. LYELL HAS SINCE COMMENCED PATIENT DOSING IN THE FIRST-OF-ITS-KIND PHASE 3 HEAD-TO-HEAD CAR T-CELL RANDOMIZED CONTROLLED CLINICAL TRIAL OF RONDECABTAGENE AUTOLEUCEL (RONDE-CEL) VERSUS INVESTIGATOR'S CHOICE OF AXICABTAGENE CILOLEUCEL (AXI-CEL) OR LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) WITH DISEASE PROGRESSION ON AT LEAST ONE PRIOR LINE OF THERAPY (PINACLE-H2H). LYELL HAS DOSED SEVEN NEW PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) WITH LYL273, AN ENHANCED GUANYLYL CYCLASE C (GCC)-TARGETED CAR T-CELL PRODUCT CANDIDATE, SINCE ITS NOVEMBER 2025 ACQUISITION, WITHOUT DOSE-LIMITING TOXICITY AND INCLUDING DOSE ESCALATION TO DOSE LEVEL 3.

LYELL IMMUNOPHARMA REPORTS Q4 AND FULL YEAR 2025 BUSINESS AND FINANCIAL RESULTS

SOUTH SAN FRANCISCO, CALIF., MARCH 09, 2026 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED IT HAS CLOSED THE SALE OF AN ADDITIONAL $50 MILLION OF SHARES OF ITS COMMON STOCK TO INVESTORS FROM ITS JULY 2025 EQUITY PRIVATE PLACEMENT OF UP TO $100 MILLION, FOLLOWING ACHIEVEMENT OF A CLINICAL MILESTONE WITHIN ITS PINACLE PIVOTAL TRIAL EVALUATING RONDECABTAGENE AUTOLEUCEL (RONDE-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL) IN THE THIRD- OR LATER-LINE SETTING. THE COMPANY ALSO ANNOUNCED THE APPOINTMENT OF SMITAL SHAH AS ITS CHIEF FINANCIAL AND BUSINESS OFFICER, EFFECTIVE MARCH 9, 2026.

LYELL IMMUNOPHARMA ANNOUNCES CLOSING OF ADDITIONAL $50 MILLION TRANCHE OF EQUITY PRIVATE PLACEMENT AND APPOINTMENT OF SMITAL SHAH AS CHIEF FINANCIAL AND BUSINESS OFFICER

Lyell Immunopharma, Inc.

LYEL

Price

Financial Reports

No items found.

Press Releases

Lyell Immunopharma, Inc.

LYEL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

LYEL